37 results
8-K
EX-10.1
ONCR
Oncorus, Inc.
19 Nov 21
Entry into a Material Definitive Agreement
4:47pm
of such indebtedness by the Company or any of its subsidiaries.
(t) No Material Actions or Proceedings. There is no action, suit, proceeding, inquiry or investigation … , investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries, and (iv) there are no events
8-K
ONCR
Oncorus, Inc.
30 Nov 22
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
7:07am
an investigation new drug application ("IND") to the U.S. Food and Drug Administration in mid-2023 to evaluate ONCR-021 in patients with non-small cell
8-K
EX-99.1
ONCR
Oncorus, Inc.
12 Nov 21
Entry into a Material Definitive Agreement
7:45am
President of Clinical Investigation, and Chief of the Melanoma Section, at the Roswell Park Comprehensive Cancer Center in Buffalo, New York
8-K
EX-99.1
9wmgn960 rmiz
10 Jan 22
Regulation FD Disclosure
8:17am
S-3
EX-4.6
z4i60oa8pksmakwe6
3 Nov 21
Shelf registration
5:00pm
DRS
EX-10.9
rkl6pvzn2j wo
31 Oct 19
Draft registration statement
12:00am
S-1
EX-10.10
zqnwrrj67mqs tu025p1
11 Sep 20
IPO registration
4:49pm
DRS
EX-10.10
o9pzfnio
31 Oct 19
Draft registration statement
12:00am
DRS/A
EX-10.1
i32matsn 8u
20 Dec 19
Draft registration statement (amended)
12:00am
S-1
EX-10.1
dol9m5f9 r49etnigg
11 Sep 20
IPO registration
4:49pm
10-Q
mpz5q pz090r67d
12 Nov 20
Quarterly report
8:01am
DRS
EX-10.21
tpv150iph6 fqkc
28 Jan 21
Draft registration statement
12:00am
DRS/A
EX-10.19
381ag3j
20 Dec 19
Draft registration statement (amended)
12:00am
S-1
EX-10.19
ky0ro9rq6hacbii0zd2
11 Sep 20
IPO registration
4:49pm
8-K
EX-10.1
2ytq0y6u3jxs6fxk0
5 Apr 22
Entry into a Material Definitive Agreement
7:10am
DRS/A
EX-3.2
g17rd
20 Dec 19
Draft registration statement (amended)
12:00am
S-1
EX-3.2
cokxg
11 Sep 20
IPO registration
4:49pm